Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Papa, Anne Laure ^a   Basu, Sudipta ^a   Sengupta, Poulomi ^a   Banerjee, Deboshri ^a   Sengupta, Shiladitya ^a,b,c   Harfouche, Rania ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Gemcitabine; Liposome; Pancreatic cancer; Poly(lactic co glycolic acid); Transmission electron microscopy

Indexed keywords

CHOLESTEROL; GEMCITABINE; LIPOSOME; NANOPARTICLE; POLYGLACTIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; CYTOSOL; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG RELEASE; ENCAPSULATION; ENDOPLASMIC RETICULUM STRESS; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; LIGHT SCATTERING; MITOCHONDRION; PANCREAS CARCINOMA; PARTICLE SIZE; PHYSICAL CHEMISTRY; SYNTHESIS; TRANSMISSION ELECTRON MICROSCOPY;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CHOLESTEROL; DEOXYCYTIDINE; HUMANS; LACTIC ACID; LIPOSOMES; MICROSCOPY, ELECTRON, TRANSMISSION; NANOTECHNOLOGY; PANCREATIC NEOPLASMS; POLYGLYCOLIC ACID;

EID: 84866488802     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-419     Document Type: Article

References (47)

1. Merl MY, Li J, Saif MW. The first-line treatment for advanced pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium. JOP 2010, 11:148-150. Orlando, FL, USA. January 22-24.
2. Pliarchopoulou K, Pectasides D. Pancreatic cancer: Current and future treatment strategies. Cancer Treat Rev 2009, 35:431-436. 10.1016/j.ctrv.2009.02.005, 19328630.
3. Harsha HC, Kandasamy K, Ranganathan P, Rani S, Ramabadran S, Gollapudi S, Balakrishnan L, Dwivedi SB, Telikicherla D, Selvan LD, Goel R, Mathivanan S, Marimuthu A, Kashyap M, Vizza RF, Mayer RJ, Decaprio JA, Srivastava S, Hanash SM, Hruban RH, Pandey A. A compendium of potential biomarkers of pancreatic cancer. PLoS Med 2009, 6:e1000046. 10.1371/journal.pmed.1000046, 2661257, 19360088.
4. Yachida S, Iacobuzio-Donahue CA. The pathology and genetics of metastatic pancreatic cancer. Arch Pathol Lab Med 2009, 133:413-422.
5. Di MM, Di CR, Macchini M, Nobili E, Vecchiarelli S, Brandi G, Biasco G. Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review). Oncol Rep 2010, 23:1183-1192.
6. Patra CR, Bhattacharya R, Wang E, Katarya A, Lau JS, Dutta S, Muders M, Wang S, Buhrow SA, Safgren SL, Yaszemski MJ, Reid JM, Ames MM, Mukherjee P, Mukhopadhyay D. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res 2008, 68:1970-1978. 10.1158/0008-5472.CAN-07-6102, 18339879.
7. Hidalgo M. Pancreatic cancer. N Engl J Med 2010, 362:1605-1617. 10.1056/NEJMra0901557, 20427809.
8. Bornmann C, Graeser R, Esser N, Ziroli V, Jantscheff P, Keck T, Unger C, Hopt UT, Adam U, Schaechtele C, von DE Massing U. A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging. Cancer Chemother Pharmacol 2008, 61:395-405. 10.1007/s00280-007-0482-z, 17554540.
9. Huanwen W, Zhiyong L, Xiaohua S, Xinyu R, Kai W, Tonghua L. Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol Cancer 2009, 8:125. 10.1186/1476-4598-8-125, 2806309, 20021699.
10. Kleynberg RL, Sofi AA, Chaudhary RT. Hand-Foot Hyperpigmentation Skin Lesions Associated With Combination Gemcitabine-Carboplatin (GemCarbo) Therapy. Am J Ther 2010, 18:e261-e263.
11. Hong SP, Wen J, Bang S, Park S, Song SY. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer 2009, 125:2323-2331. 10.1002/ijc.24573, 19598259.
12. Reid JM, Qu W, Safgren SL, Ames MM, Krailo MD, Seibel NL, Kuttesch J, Holcenberg J. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. J Clin Oncol 2004, 22:2445-2451. 10.1200/JCO.2004.10.142, 15197207.
13. Rapoport N, Kennedy AM, Shea JE, Scaife CL, Nam KH. Ultrasonic nanotherapy of pancreatic cancer: lessons from ultrasound imaging. Mol Pharm 2010, 7:22-31. 10.1021/mp900128x, 2815246, 19899813.
14. Pedersen AG. Phase I studies of gemcitabine combined with carboplatin or paclitaxel. Semin Oncol 1997, 24:S7.
15. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J 2005, 19:311-330. 10.1096/fj.04-2747rev, 15746175.
16. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782. 10.1038/nrd2614, 18758474.
17. Stavridi F, Palmieri C. Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer. Expert Rev Anticancer Ther 2008, 8:1859-1869. 10.1586/14737140.8.12.1859, 19046106.
18. Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res 2006, 23:1417-1450. 10.1007/s11095-006-0284-8, 16779701.
19. Kim JS, Yoon TJ, Yu KN, Noh MS, Woo M, Kim BG, Lee KH, Sohn BH, Park SB, Lee JK, Cho MH. Cellular uptake of magnetic nanoparticle is mediated through energy-dependent endocytosis in A549 cells. J Vet Sci 2006, 7:321-326. 10.4142/jvs.2006.7.4.321, 3242138, 17106221.
20. Pili B, Reddy LH, Bourgaux C, Lepetre-Mouelhi S, Desmaele D, Couvreur P. Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation. Nanoscale 2010, 2:1521-1526. 10.1039/c0nr00132e, 20820745.
21. Papa AL, Dumont L, Vandroux D, Millot N. Titanate nanotubes: towards a novel and safer nanovector for cardiomyocytes. Nanotoxicology 2012, in press.
22. Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, Sasisekharan R. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005, 436:568-572. 10.1038/nature03794, 16049491.
23. Basu S, Harfouche R, Soni S, Chimote G, Mashelkar RA, Sengupta S. Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proc Natl Acad Sci USA 2009, 106:7957-7961. 10.1073/pnas.0902857106, 2683142, 19383798.
24. Harfouche R, Basu S, Soni S, Hentschel DM, Mashelkar RA, Sengupta S. Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis 2009, 12:325-338. 10.1007/s10456-009-9154-4, 19685150.
25. Celano M, Calvagno MG, Bulotta S, Paolino D, Arturi F, Rotiroti D, Filetti S, Fresta M, Russo D. Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells. BMC Cancer 2004, 4:63. 10.1186/1471-2407-4-63, 517941, 15363094.
26. Cosco D, Bulotta A, Ventura M, Celia C, Calimeri T, Perri G, Paolino D, Costa N, Neri P, Tagliaferri P, Tassone P, Fresta M. In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer. Cancer Chemother Pharmacol 2009, 64:1009-1020. 10.1007/s00280-009-0957-1, 19263052.
27. Cosco D, Paolino D, Cilurzo F, Casale F, Fresta M. Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases. Int J Pharm 2012, 422:229-237. 10.1016/j.ijpharm.2011.10.056, 22093954.
28. Trickler WJ, Khurana J, Nagvekar AA, Dash AK. Chitosan and glyceryl monooleate nanostructures containing gemcitabine: potential delivery system for pancreatic cancer treatment. AAPS PharmSciTech 2010, 11:392-401. 10.1208/s12249-010-9393-0, 2850475, 20238190.
29. Tewes F, Munnier E, Antoon B, Ngaboni OL, Cohen-Jonathan S, Marchais H, Douziech-Eyrolles L, Souce M, Dubois P, Chourpa I. Comparative study of doxorubicin-loaded poly(lactide-co-glycolide) nanoparticles prepared by single and double emulsion methods. Eur J Pharm Biopharm 2007, 66:488-492. 10.1016/j.ejpb.2007.02.016, 17433641.
30. Niu G, Cogburn B, Hughes J. Preparation and characterization of doxorubicin liposomes. Methods Mol Biol 2010, 624:211-219. 10.1007/978-1-60761-609-2_14, 20217598.
31. Sunoqrot S, Bae JW, Jin SE, Pearson M, Liu Y, Hong S. Kinetically controlled cellular interactions of polymer-polymer and polymer-liposome nanohybrid systems. Bioconjug Chem 2011, 22:466-474. 10.1021/bc100484t, 3059376, 21344902.
32. Canton I, Battaglia G. Endocytosis at the nanoscale. Chem Soc Rev 2012, 41:2718-2739. 10.1039/c2cs15309b, 22389111.
33. Alber F, Dokudovskaya S, Veenhoff LM, Zhang W, Kipper J, Devos D, Suprapto A, Karni-Schmidt O, Williams R, Chait BT, Sali A, Rout MP. The molecular architecture of the nuclear pore complex. Nature 2007, 450:695-701. 10.1038/nature06405, 18046406.
34. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001, 70:1-20. 10.1016/S0168-3659(00)00339-4, 11166403.
35. Hasirci V, Lewandrowski K, Gresser JD, Wise DL, Trantolo DJ. Versatility of biodegradable biopolymers: degradability and an in vivo application. J Biotechnol 2001, 86:135-150. 10.1016/S0168-1656(00)00409-0, 11245902.
36. Reddy KR. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann Pharmacother 2000, 34:915-923.
37. Paillard A, Hindre F, Vignes-Columbeix C, Benoit JP, Garcion E. The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability. Biomaterials 2010, 31:7542-7554. 10.1016/j.biomaterials.2010.06.024, 20630585.
38. Resina S, Prevot P, Thierry AR. Physico-chemical characteristics of lipoplexes influence cell uptake mechanisms and transfection efficacy. PLoS One 2009, 4:e6058. 10.1371/journal.pone.0006058, 2699663, 19557145.
39. Dandekar P, Jain R, Stauner T, Loretz B, Koch M, Wenz G, Lehr CM. A Hydrophobic Starch Polymer for Nanoparticle-Mediated Delivery of Docetaxel. Macromol Biosci 2011, 12:184-194.
40. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 2004, 377:159-169. 10.1042/BJ20031253, 1223843, 14505488.
41. Bakeeva LE, Skulachev VP, Sudarikova YV, Tsyplenkova VG. Mitochondria enter the nucleus (one further problem in chronic alcoholism). Biochemistry (Mosc) 2001, 66:1335-1341.
42. Vaquero EC, Rickmann M, Molero X. Tocotrienols: balancing the mitochondrial crosstalk between apoptosis and autophagy. Autophagy 2007, 3:652-654.
43. Donadelli M, Dando I, Zaniboni T, Costanzo C, Dalla PE, Scupoli MT, Scarpa A, Zappavigna S, Marra M, Abbruzzese A, Bifulco M, Caraglia M, Palmieri M. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis 2011, 2:e152. 10.1038/cddis.2011.36, 3122066, 21525939.
44. Fujita R, Ueda H. Protein kinase C-mediated necrosis-apoptosis switch of cortical neurons by conditioned medium factors secreted under the serum-free stress. Cell Death Differ 2003, 10:782-790. 10.1038/sj.cdd.4401239, 12815461.
45. Ghadially FN. Ultrastructural Pathology of the Cell and Matrix 1997, 1. Butterworth-Heineman, Boston, 4.
46. Kanzaki Y, Terasaki F, Okabe M, Otsuka K, Katashima T, Fujita S, Ito T, Kitaura Y. Giant mitochondria in the myocardium of a patient with mitochondrial cardiomyopathy: transmission and 3-dimensional scanning electron microscopy. Circulation 2010, 121:831-832. 10.1161/CIR.0b013e3181d22e2d, 20159843.
47. Meares GP, Mines MA, Beurel E, Eom TY, Song L, Zmijewska AA, Jope RS. Glycogen synthase kinase-3 regulates endoplasmic reticulum (ER) stress-induced CHOP expression in neuronal cells. Exp Cell Res 2011, 317:1621-1628. 10.1016/j.yexcr.2011.02.012, 3103628, 21356208.